Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04337138 · ClinicalTrials.gov registry record
A Study Of Treatment Patterns And Clinical Outcomes In Patients Diagnosed With Acute Myeloid Leukemia Who Received Mylotarg in the Real-World
A clinical trial of Leukemia, Myeloid, Acute, sponsored by Pfizer.
- Completed
- Registry status
- 32
- Enrollment target
- 1
- Study location
NCT04337138 is a study of Leukemia, Myeloid, Acute that has completed, run by Pfizer. The registered enrollment target is 32 participants, below the 115-participant average among 30 other Leukemia, Myeloid, Acute trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04337138, a study of Leukemia, Myeloid, Acute, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this observational study is to describe treatment patterns and effectiveness outcomes in a sample of oncology patients treated for AML with Mylotarg through up to two additional relapsed/refractory (R/R)-based lines of therapy (through third-line therapy). The study will use United States oncology electronic medical record (EMR) data. All study data are secondary data and will have been collected retrospectively from existing clinical data originally collected as part of routine care.
Conditions Studied
Interventions
- DRUG Gemtuzumab Ozogamicin
Study Locations (1)
New York
- Pfizer Investigational Site - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2020-04-07 |
| Est. Completion | 2020-07-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04337138
The ClinicalTrials.gov registry entry for NCT04337138 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 115-participant average among 30 other Leukemia, Myeloid, Acute trials with a reported enrollment target (72% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukemia, Myeloid, Acute appearing as the primary indexed condition, and to 1 intervention - of which Gemtuzumab Ozogamicin is the first listed.
NCT04337138 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04337138 about?
NCT04337138 is a clinical study titled "A Study Of Treatment Patterns And Clinical Outcomes In Patients Diagnosed With Acute Myeloid Leukemia Who Received Mylotarg in the Real-World". The aim of this observational study is to describe treatment patterns and effectiveness outcomes in a sample of oncology patients treated for AML with Mylotarg through up to two additional relapsed/refractory (R/R)-based lines of therapy (through third-line therapy). The study will use United States...
What is the current status of trial NCT04337138?
This trial is currently completed. The enrollment target is 32 participants. The study started on 2020-04-07. Estimated completion is 2020-07-31.
What conditions does trial NCT04337138 study?
This clinical trial studies the following conditions: Leukemia, Myeloid, Acute.
What interventions are being tested in trial NCT04337138?
The interventions under investigation include: Gemtuzumab Ozogamicin (DRUG).
Who is sponsoring clinical trial NCT04337138?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04337138 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia, Myeloid, Acute
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
RECRUITING · Phase 3
-
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy
RECRUITING · Phase 2
-
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
RECRUITING · Phase 2
-
Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.